Diagnostic and therapeutic challenges in chronic inflammatory demyelinating polyneuropathy and other immune-mediated neuropathies

Author(s): Magy L, Mathis S, Vallat JM

Abstract

Purpose of review:Immune-mediated neuropathies are increasingly recognized as potential causes of disability. Their diagnostic criteria and management options are still a matter of debate. This review focuses on recent findings in the diagnostic and therapeutic management of these disorders and on their prognostic factors.

Recent findings:The more widespread use of consensus criteria has improved diagnostic strategies for immune-mediated neuropathies. Studies of large prospective series have defined the spectrum of these disorders and their respective prognoses. Although treatment of these disorders mostly relies on corticosteroids and intravenous immunoglobulin, recent controlled trials have indicated the value of targeted immunotherapies. The further development of these therapies requires better understanding of the pathophysiology of these disorders. Immunological and immunopathological studies have improved our understanding of immune-mediated neuropathies over the last few years.

Summary:Identifying immune-mediated neuropathies is important, as these disorders are treatable. Diagnostic strategies have improved our capacity to recognize affected patients who can be offered effective treatments. Therapeutic options for immune-mediated neuropathies are still rather limited, although targeted immunotherapies may improve the prognosis of these disorders in the near future.

Similar Articles

Safety of intravenous immunoglobulin (IVIG) therapy

Author(s): Katz U, Achiron A, Sherer Y, Shoenfeld Y

Intravenous immunoglobulin: adverse effects and safe administration

Author(s): Orbach H, Katz U, Sherer Y, Shoenfeld Y

Complications of intravenous immune globulin treatment in neurologic disease

Author(s): Brannagan TH 3rd, Nagle KJ, Lange DJ, Rowland LP

Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome

Author(s): Chamouni P, Tamion F, Gueit I, Girault C, Lenain P, et al.

Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy

Author(s): Guptill JT, Bromberg MB, Zhu L, Sharma BK, Thompson AR, et al.

Diffuse muscular coactivation [DMC] as a potential source of pain in fibromyalgia -- part 1

Author(s): Donaldson CC, Snelling LS, MacInnis AL, Sella GE, Mueller HH

Pregabalin for fibromyalgia: some relief but no cure

Author(s): Kim L, Lipton S, Deodhar A

The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome

Author(s): Russell IJ, Crofford LJ, Leon T, Cappelleri JC, Bushmakin AG, et al.

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia

Author(s): Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, et al.

Prevalence and factors associated with fibromyalgia in Mexican patients with systemic lupus erythematosus

Author(s): Valencia-Flores M, Cardiel MH, Santiago V, Resendiz M, Castaño VA, et al.

The prevalence and characteristics of fibromyalgia in the general population

Author(s): Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States

Author(s): Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, et al.

Prevalence of fibromyalgia in children: a clinical study of Mexican children

Author(s): Clark P, Burgos-Vargas R, Medina-Palma C, Lavielle P, Marina FF

Management of fibromyalgia syndrome

Author(s): Goldenberg DL, Burckhardt C, Crofford L

Fibromyalgia syndrome module at OMERACT 9: domain construct

Author(s): Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, et al.

Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update

Author(s): Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, et al.

Nerve ultrasound score in distinguishing chronic from acute inflammatory demyelinating polyneuropathy

Author(s): Kerasnoudis A, Pitarokoili K, Behrendt V, Gold R, Yoon MS

Clinical spectrum of chronic acquired demyelinating polyneuropathies

Author(s): Saperstein DS, Katz JS, Amato AA, Barohn RJ

Chronic inflammatory demyelinating polyradiculoneuropathy

Author(s): Barohn RJ, Kissel JT, Warmolts JR, Mendell JR

Chronic inflammatory polyradiculoneuropathy

Author(s): Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, et al.

Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy

Author(s): Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, et al.

IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

Author(s): Ritter C, Förster D, Albrecht P, Hartung HP, Kieseier BC, et al.

Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy

Author(s): Cocito D, Grimaldi S, Paolasso I, Falcone Y, Antonini G, et al.

High prevalence of restless legs syndrome among patients with fibromyalgia: a controlled cross-sectional study

Author(s): Viola-Saltzman M, Watson NF, Bogart A, Goldberg J, Buchwald D